Non-Invasive HCC Surveillance Strategies Debated for MASLD Patients
Researchers respond to peer critique of risk-based, non-invasive hepatocellular carcinoma surveillance in metabolic liver disease patients.
Summary
This correspondence from researchers at The Chinese University of Hong Kong responds to a letter challenging their earlier work on non-invasive, risk-stratified surveillance for hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD, formerly known as NAFLD, is the fastest-growing cause of liver cancer worldwide, yet optimal surveillance strategies remain debated. The authors defend their approach of using non-invasive risk markers rather than universal screening, arguing it better targets high-risk individuals while reducing unnecessary procedures. This exchange reflects an active scientific debate about how to identify which MASLD patients truly need HCC monitoring — a clinically urgent question given the rising global burden of metabolic liver disease and its cancer complications.
Detailed Summary
Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, and metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly becoming its most common underlying cause. As MASLD affects hundreds of millions worldwide, determining who needs HCC surveillance — and how to conduct it without invasive procedures — is a pressing clinical challenge.
This publication is a reply letter from Lai and Yip at The Chinese University of Hong Kong, responding to a critique by Gao and Liu regarding the authors' original research on non-invasive, risk-based HCC surveillance in MASLD patients. The original study proposed stratifying patients by risk level using non-invasive markers rather than applying uniform surveillance to all MASLD patients.
While the specific arguments exchanged are not detailed in the available abstract, such correspondence typically involves defending methodological choices, clarifying statistical approaches, and addressing concerns about generalizability or clinical applicability. The authors are affiliated with the Medical Data Analytics Centre, suggesting their original work likely leveraged large-scale real-world data and predictive modeling.
The clinical implications are significant. Current guidelines vary on whether MASLD patients without cirrhosis should receive routine HCC surveillance. A validated, non-invasive risk-stratification tool could help clinicians identify the subset of MASLD patients at genuinely elevated HCC risk, enabling targeted ultrasound or biomarker monitoring while sparing low-risk patients unnecessary procedures and costs.
Caveats are notable: this is a reply letter, not a primary research article, meaning no new data are presented. The summary is based solely on the abstract and publication metadata. Additionally, both authors disclosed advisory and speaking relationships with pharmaceutical companies including Gilead Sciences, GSK, and Boehringer Ingelheim, which warrants consideration when interpreting their positions in this scientific debate.
Key Findings
- Authors defend non-invasive, risk-stratified HCC surveillance as preferable to universal screening in MASLD patients.
- MASLD is a rapidly growing driver of hepatocellular carcinoma, making surveillance strategy optimization clinically urgent.
- Risk-based approaches aim to target high-risk individuals while reducing unnecessary procedures for low-risk patients.
- This exchange highlights ongoing scientific debate about optimal HCC monitoring in metabolic liver disease.
- Both authors disclosed industry ties to Gilead, GSK, and Boehringer Ingelheim, relevant context for the debate.
Methodology
This is a reply letter to a published critique, not a primary research study. No new methodology or data are presented in this correspondence. The original research being defended likely used real-world clinical data and non-invasive biomarker modeling, given the authors' affiliation with a medical data analytics center.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; the specific arguments and data referenced in the reply are unavailable. This is a correspondence piece, not a primary research article, so no new findings are introduced. Author conflicts of interest with multiple pharmaceutical companies should be considered when evaluating the positions expressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.